The Quantellect read.As of Nov 19, 2026, 4 active firms cover Prelude Therapeutics Inc: 4 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $6.00 to $12.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $8.75 sits 165% above the current $3.30. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 3 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.16 next quarter toward $-0.47 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Buy
Strong Buy00%
Buy4100%
Neutral00%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$8.75
+165.2% upside
Average target across 4 active firms as of Nov 19, 2026 vs $3.30 current
Highest Target$12.00
Average Target$8.75
Lowest Target$6.00
Detailed analyst forecasts for PRLD
Showing 1–4 of 4 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 4 of 4 active firms rate PRLD a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
PRLD EPS & revenue forecast
EPS · NEXT QUARTER
$-0.16
Range $-0.18 – $-0.14 · 4 analysts · +21% YoY
Next period, 4 analysts expect Prelude Therapeutics Inc to earn $-0.16 a share (range $-0.18 – $-0.14), versus $-0.13 a year earlier. Full-year consensus is $-0.53, growing to $-0.47 the year after.
REVENUE · NEXT QUARTER
$5.0M
Range $4.6M – $5.5M · 4 analysts · +10% YoY
Revenue is expected to reach $5.0M (range $4.6M – $5.5M), +10.1% year-over-year. Full-year consensus is $21.2M, rising to $39.3M next year.
Top analysts covering Prelude Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PRLD.
#1
RB
Robert Burns
HC Wainwright & Co. · Rank #215
Buy
$8.00+142.4% to target
Overall win rate
42%
+ Follow
#2
Reni J. Benjamin
JMP Securities · Rank #489
Buy
$6.00+81.8% to target
Overall win rate
29%
+ Follow
#3
Jason Kolbert
D. Boral Capital · Rank #562
Buy
$9.00+172.7% to target
Overall win rate
22%
+ Follow
#4
Reni J. Benjamin
Citizens
Buy
$6.00+81.8% to target
Coverage
—
+ Follow
PRLD stock forecast FAQ
What is PRLD's average 12-month price target?+
The 4 active firms with a live target average $8.75 for Prelude Therapeutics Inc over the next 12 months, ranging from a $12.00 high to a $6.00 low, as of Nov 19, 2026.
Is PRLD stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 4 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for PRLD?+
The Street-high target is $12.00 (JP Morgan), and the Street-low is $6.00 (Citizens). The average of all 4 active-firm targets is $8.75.
How many active Wall Street firms cover PRLD?+
4 active firms have a recognized rating on Prelude Therapeutics Inc as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering PRLD?+
Among analysts who currently cover PRLD, Robert Burns of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #215). Their current call is Buy with a $8.00 target.
What is Prelude Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.16 per share (range $-0.18 – $-0.14) across 4 analysts. Full-year EPS is projected at $-0.53, rising to $-0.47 the following year.
How much revenue is Prelude Therapeutics Inc expected to report next quarter?+
Consensus revenue is $5.0M (range $4.6M – $5.5M). Full-year revenue is projected at $21.2M, growing to $39.3M next year.
Have analysts been upgrading or downgrading PRLD lately?+
As of Nov 19, 2026, 4 of 4 active firms rate PRLD a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PRLD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.